Åslaug Helland

  • Professor, group leader; MD, PhD
  • +47 22 78 14 85/ 93 45 27

Professor in oncology, University of Oslo
Research Director, Oslo Comprehensive Cancer Centre
Group leader, Institute for Cancer Research, Oslo University Hospital

For CV, see LinkedIn: Åslaug Helland

 

Publications 2024

Brativnyk A, Ankill J, Helland Å, Fleischer T (2024)
Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
Int J Cancer (in press)
DOI 10.1002/ijc.34915, PubMed 38489486

Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
[Not Available]
Tidsskr Nor Laegeforen, 144 (1)
DOI 10.4045/tidsskr.23.0740, PubMed 38258713

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Eur J Cancer, 202, 113973 (in press)
DOI 10.1016/j.ejca.2024.113973, PubMed 38447379

Mahon P, Chatzitheofilou I, Dekker A, Fernández X, Hall G, Helland A, Traverso A, Van Marcke C, Vehreschild J, Ciliberto G, Tonon G (2024)
A federated learning system for precision oncology in Europe: DigiONE
Nat Med, 30 (2), 334-337
DOI 10.1038/s41591-023-02715-8, PubMed 38195748

Nilssen Y, Brustugun OT, Fjellbirkeland L, Helland Å, Møller B, Wahl SGF, Solberg S (2024)
Distribution and characteristics of malignant tumours by lung lobe
BMC Pulm Med, 24 (1), 106
DOI 10.1186/s12890-024-02918-w, PubMed 38439038

Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, Heard E, Heitor M, Chandy M, Chen CJ, Costa A, De Lorenzo F, De Robertis EM, Dubee FC, Ernberg I, Gabriel M, Helland Å, Henrique R, Jönsson B, Kallioniemi O, Korbel J, Krause M, Lowy DR, Michielin O, Nagy P et al. (2024)
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023
Mol Oncol, 18 (2), 245-279
DOI 10.1002/1878-0261.13575, PubMed 38135904

Publications 2023

Børø S, Thoresen S, Boge Brant S, Helland Å (2023)
Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer
Acta Oncol, 62 (12), 1642-1648
DOI 10.1080/0284186X.2023.2264484, PubMed 37801361

Helland Å, Myklebust TÅ, Conte S, Frederiksen LE, Aarøe J, Enerly E (2023)
EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study
Cancer Treat Res Commun, 38, 100785
DOI 10.1016/j.ctarc.2023.100785, PubMed 38190787

Huynh TM, Dale E, Falk RS, Hellebust TP, Astrup GL, Malinen E, Edin NFJ, Bjordal K, Herlofson BB, Kiserud CE, Helland Å, Amdal CD (2023)
Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters
Radiother Oncol, 190, 110044
DOI 10.1016/j.radonc.2023.110044, PubMed 38061420

Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
Front Oncol, 13, 1217424
DOI 10.3389/fonc.2023.1217424, PubMed 37476372

Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A (2023)
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
Eur J Cancer, 194, 113278
DOI 10.1016/j.ejca.2023.113278, PubMed 37820553

Nilssen Y, Solberg S, Brustugun OT, Møller B, Sundset A, Wahl SGF, Helland Å (2023)
Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
Eur J Cardiothorac Surg, 64 (1)
DOI 10.1093/ejcts/ezad244, PubMed 37348858

Ottesen JA, Yi D, Tong E, Iv M, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Bjørnerud A, Zaharchuk G, Grøvik E (2023)
2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
Front Neuroinform, 16, 1056068
DOI 10.3389/fninf.2022.1056068, PubMed 36743439

Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
New centres to carry out more clinical trials in Norway
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0722, PubMed 36718905

Yi D, Grøvik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland Å, Zaharchuk G, Rubin D (2023)
Erratum: "MRI pulse sequence integration for deep-learning-based brain metastases segmentation"
Med Phys, 50 (8), 5294
DOI 10.1002/mp.16594, PubMed 37573581

Publications 2022

Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
Front Immunol, 13, 875152
DOI 10.3389/fimmu.2022.875152, PubMed 35911763

Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer
Front Immunol, 13, 1051156
DOI 10.3389/fimmu.2022.1051156, PubMed 36263024

Børø S, Thoresen S, Helland Å (2022)
Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 - 2020 - A population-based registry study from Norway
Front Oncol, 12, 1017902
DOI 10.3389/fonc.2022.1017902, PubMed 36523970

Chen J, Song Y, Li Y, Wei Y, Shen S, Zhao Y, You D, Su L, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Shen H, Christiani DC, Zhang R, Chen F (2022)
A trans-omics assessment of gene-gene interaction in early-stage NSCLC
Mol Oncol, 17 (1), 173-187
DOI 10.1002/1878-0261.13345, PubMed 36408734

Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT (2022)
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Transl Lung Cancer Res, 11 (6), 953-963
DOI 10.21037/tlcr-21-995, PubMed 35832438

Helland Å, Andersen KK, Myklebust TÅ, Johannesen TB, Aarøe J, Enerly E (2022)
EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
Cancer Treat Res Commun, 33, 100636
DOI 10.1016/j.ctarc.2022.100636, PubMed 36155129

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045

Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
Mol Oncol, 17 (3), 487-498
DOI 10.1002/1878-0261.13330, PubMed 36330681

Ji X, Lin L, Fan J, Li Y, Wei Y, Shen S, Su L, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Zhang R, Chen F, Christiani DC (2022)
Epigenome-wide three-way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of early-stage NSCLC
Mol Oncol, 16 (3), 717-731
DOI 10.1002/1878-0261.13167, PubMed 34932879

Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
Front Oncol, 12, 873532
DOI 10.3389/fonc.2022.873532, PubMed 35574381

Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
Front Oncol, 12, 1031232
DOI 10.3389/fonc.2022.1031232, PubMed 36439452

Silwal-Pandit L, Stålberg SM, Henrik J. Johansson, Georgios Mermelekas, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal D, Helland, Lingjærde OC, Labori KJ, Skålhegg BS, Janne Lehtiö, Kure EH (2022)
Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
Cancer Res Commun, 2 (6), 434-446
DOI 10.1158/2767-9764.CRC-21-0100, PublikaID 411

Silwal-Pandit L, Stålberg SM, Johansson HJ, Mermelekas G, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal DJH, Helland Å, Lingjærde OC, Labori KJ, Skålhegg BS, Lehtiö J, Kure EH (2022)
Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
Cancer Res Commun, 2 (6), 434-446
DOI 10.1158/2767-9764.CRC-21-0100, PubMed 36923555

Solberg S, Nilssen Y, Terje Brustugun O, Magnus Haram P, Helland Å, Møller B, Strand TE, Gyrid Freim Wahl S, Fjellbirkeland L (2022)
Concordance between clinical and pathology TNM-staging in lung cancer
Lung Cancer, 171, 65-69
DOI 10.1016/j.lungcan.2022.07.014, PubMed 35926242

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529

Umu SU, Langseth H, Zuber V, Helland Å, Lyle R, Rounge TB (2022)
Serum RNAs can predict lung cancer up to 10 years prior to diagnosis
Elife, 11
DOI 10.7554/eLife.71035, PubMed 35147498

Publications 2021

Berg J, Ramberg C, Haugstvedt JOS, Bengtson MB, Gabrielsen AM, Brustugun OT, Halvorsen AR, Helland Å (2021)
Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
Front Oncol, 11, 674731
DOI 10.3389/fonc.2021.674731, PubMed 34109123

Bjaanæs MM, Nilsen G, Halvorsen AR, Russnes HG, Solberg S, Jørgensen L, Brustugun OT, Lingjærde OC, Helland Å (2021)
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
BMC Cancer, 21 (1), 1089
DOI 10.1186/s12885-021-08811-7, PubMed 34625038

Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Acta Oncol, 60 (12), 1565-1571
DOI 10.1080/0284186X.2021.1973092, PubMed 34486915

Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
[Immunotherapy for malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0503, PubMed 34505475

Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
Immunotherapy in malignant pleural mesothelioma
Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169

Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2021)
The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
Front Immunol, 12, 764596
DOI 10.3389/fimmu.2021.764596, PubMed 34868011

Grøvik E, Yi D, Iv M, Tong E, Nilsen LB, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Zaharchuk G (2021)
Handling missing MRI sequences in deep learning segmentation of brain metastases: a multicenter study
NPJ Digit Med, 4 (1), 33
DOI 10.1038/s41746-021-00398-4, PubMed 33619361

Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094

Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland Å (2021)
COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
Front Oncol, 11, 652535
DOI 10.3389/fonc.2021.652535, PubMed 33842366

Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung JY, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, Bar J (2021)
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
J Thorac Oncol, 16 (9), 1570-1581
DOI 10.1016/j.jtho.2021.03.012, PubMed 33823285

Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ et al. (2021)
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
Nat Cancer, 2 (11), 1224-1242
DOI 10.1038/s43018-021-00259-9, PubMed 34870237

Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland Å, Hochmair M, Pérol M, Bent-Ennakhil N, Kruhl C, Novello S (2021)
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
Lung Cancer, 157, 9-16
DOI 10.1016/j.lungcan.2021.05.017, PubMed 34051652

Yi D, Grøvik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland Å, Zaharchuk G, Rubin D (2021)
MRI pulse sequence integration for deep-learning-based brain metastases segmentation
Med Phys, 48 (10), 6020-6035
DOI 10.1002/mp.15136, PubMed 34405896

Öjlert ÅK, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, Chee J, Helland Å (2021)
Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
Mol Oncol, 15 (11), 2958-2968
DOI 10.1002/1878-0261.13082, PubMed 34402187

Publications 2020

Abravan A, Eide HA, Helland Å, Malinen E (2020)
Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
Clin Transl Radiat Oncol, 22, 15-21
DOI 10.1016/j.ctro.2020.02.005, PubMed 32181373

Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
Lung cancer: Improved prognosis presents capacity challenges
Tidsskr. Nor. Laegeforen., 140 (5), 432-434

Brustugun OT, Sørhaug S, Grønberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland Å, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
[Lung cancer: Improved prognosis results in capacity challenges]
Tidsskr Nor Laegeforen, 140 (5)
DOI 10.4045/tidsskr.20.0014, PubMed 32238965

Chen C, Wei Y, Wei L, Chen J, Chen X, Dong X, He J, Lin L, Zhu Y, Huang H, You D, Lai L, Shen S, Duan W, Su L, Shafer A, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Zhang R et al. (2020)
Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
Aging (Albany NY), 12 (11), 10642-10662
DOI 10.18632/aging.103284, PubMed 32511103

Digernes I, Nilsen LB, Grøvik E, Bjørnerud A, Løvland G, Vik-Mo E, Meling TR, Saxhaug C, Helland Å, Jacobsen KD, Geier O, Emblem KE (2020)
Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI
Phys Med Biol, 65 (22), 225020
DOI 10.1088/1361-6560/abb71a, PubMed 33200748

Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138

Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
Antibody combinations for optimized staining of macrophages in human lung tumours
Scand J Immunol, 92 (1), e12889
DOI 10.1111/sji.12889, PubMed 32299134

Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
DOI 10.3389/fonc.2020.590755, PubMed 33324562

Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587

Ji X, Lin L, Shen S, Dong X, Chen C, Li Y, Zhu Y, Huang H, Chen J, Chen X, Wei L, He J, Duan W, Su L, Jiang Y, Fan J, Guan J, You D, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M et al. (2020)
Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
Mol Oncol, 14 (11), 2759-2774
DOI 10.1002/1878-0261.12785, PubMed 33448640

Nilsen LB, Digernes I, Grøvik E, Saxhaug C, Latysheva A, Geier O, Breivik B, Sætre DO, Jacobsen KD, Helland Å, Emblem KE (2020)
Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
Neurooncol Adv, 2 (1), vdaa028
DOI 10.1093/noajnl/vdaa028, PubMed 32642687

Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774

Umu SU, Langseth H, Keller A, Meese E, Helland Å, Lyle R, Rounge TB (2020)
A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
Mol Oncol, 14 (2), 235-247
DOI 10.1002/1878-0261.12620, PubMed 31851411

Zhang R, Chen C, Dong X, Shen S, Lai L, He J, You D, Lin L, Zhu Y, Huang H, Chen J, Wei L, Chen X, Li Y, Guo Y, Duan W, Liu L, Su L, Shafer A, Fleischer T, Moksnes Bjaanæs M, Karlsson A, Planck M, Wang R, Staaf J et al. (2020)
Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
Chest, 158 (2), 808-819
DOI 10.1016/j.chest.2020.01.048, PubMed 32113923

Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å (2020)
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
Acta Oncol, 60 (2), 149-156
DOI 10.1080/0284186X.2020.1854851, PubMed 33356733

Publications 2019

Abravan A, Eide HA, Løndalen AM, Helland Å, Malinen E (2019)
Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
Mol Imaging Biol, 21 (2), 391-398
DOI 10.1007/s11307-018-1226-7, PubMed 29916117

Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland Å, Sørlie T, Haakensen VD (2019)
A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
J Mammary Gland Biol Neoplasia, 24 (2), 163-175
DOI 10.1007/s10911-018-09423-x, PubMed 30613869

Dong X, Zhang R, He J, Lai L, Alolga RN, Shen S, Zhu Y, You D, Lin L, Chen C, Zhao Y, Duan W, Su L, Shafer A, Salama M, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Wei Y, Chen F et al. (2019)
Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma
Aging (Albany NY), 11 (16), 6312-6335
DOI 10.18632/aging.102189, PubMed 31434796

Halvorsen AR, Ragle Aure M, Õjlert ÅK, Brustugun OT, Solberg S, Nebdal D, Helland Å (2019)
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
Mol Oncol, 13 (12), 2604-2615
DOI 10.1002/1878-0261.12571, PubMed 31505091

Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
PathTracer: High-sensitivity detection of differential pathway activity in tumours
Sci Rep, 9 (1), 16332
DOI 10.1038/s41598-019-52529-3, PubMed 31704995

Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T (2019)
EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
PLoS One, 14 (1), e0204186
DOI 10.1371/journal.pone.0204186, PubMed 30703089

Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L (2019)
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Eur J Epidemiol, 34 (10), 951-955
DOI 10.1007/s10654-019-00536-z, PubMed 31313073

Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2019)
Immune Cell Composition in Human Non-small Cell Lung Cancer
Front Immunol, 9, 3101
DOI 10.3389/fimmu.2018.03101, PubMed 30774636

Zhang R, Lai L, Dong X, He J, You D, Chen C, Lin L, Zhu Y, Huang H, Shen S, Wei L, Chen X, Guo Y, Liu L, Su L, Shafer A, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y et al. (2019)
SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis
Mol Oncol, 13 (5), 1235-1248
DOI 10.1002/1878-0261.12482, PubMed 30924596

Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, Guo Y, Su L, Shafer A, Moran S, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC (2019)
EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC
Epigenetics, 14 (2), 118-129
DOI 10.1080/15592294.2019.1573066, PubMed 30665327

Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å (2019)
The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
Mol Oncol, 13 (5), 1166-1179
DOI 10.1002/1878-0261.12475, PubMed 30854794

Publications 2018

Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
BMC Cancer, 18 (1), 739
DOI 10.1186/s12885-018-4659-0, PubMed 30005623

Brustugun OT, Grønberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland Å, Møller B, Nilssen Y, Strand TE, Solberg SK (2018)
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Lung Cancer, 122, 138-145
DOI 10.1016/j.lungcan.2018.06.003, PubMed 30032822

Digernes I, Grøvik E, Nilsen LB, Saxhaug C, Geier O, Reitan E, Sætre DO, Breivik B, Reese T, Jacobsen KD, Helland Å, Emblem KE (2018)
Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery
Adv Radiat Oncol, 3 (4), 559-567
DOI 10.1016/j.adro.2018.05.005, PubMed 30370356

Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv Radiat Oncol, 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007, PubMed 29904737

Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L (2018)
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
J Thorac Oncol, 13 (12), 1906-1918
DOI 10.1016/j.jtho.2018.08.2027, PubMed 30217492

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM et al. (2018)
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Nat Commun, 9 (1), 1048
DOI 10.1038/s41467-018-03099-x, PubMed 29535388

Guo Y, Zhang R, Shen S, Wei Y, Salama SM, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Su L, Zhu Z, Staaf J, Helland Å, Esteller M, Christiani DC (2018)
DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients
Cancer Epidemiol Biomarkers Prev, 27 (12), 1527-1535
DOI 10.1158/1055-9965.EPI-18-0454, PubMed 30185536

Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
Acta Oncol, 57 (9), 1225-1231
DOI 10.1080/0284186X.2018.1465585, PubMed 29683761

Helland A (2018)
Groundbreaking basic research
Tidsskr. Nor. Laegeforen., 138 (20), 1905

Helland Å (2018)
[Groundbreaking basic research]
Tidsskr Nor Laegeforen, 138 (20)
DOI 10.4045/tidsskr.18.0802, PubMed 30539600

Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG (2018)
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
Mol Oncol, 12 (11), 1838-1855
DOI 10.1002/1878-0261.12375, PubMed 30133130

Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC (2018)
A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer
Mol Oncol, 12 (6), 913-924
DOI 10.1002/1878-0261.12204, PubMed 29656435

Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I (2018)
N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
Mol Oncol, 12 (6), 972-990
DOI 10.1002/1878-0261.12312, PubMed 29698574

Wei Y, Liang J, Zhang R, Guo Y, Shen S, Su L, Lin X, Moran S, Helland Å, Bjaanæs MM, Karlsson A, Planck M, Esteller M, Fleischer T, Staaf J, Zhao Y, Chen F, Christiani DC (2018)
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
Clin Epigenetics, 10, 41
DOI 10.1186/s13148-018-0474-3, PubMed 29619118

Publications 2017

Abravan A, Eide HA, Knudtsen IS, Løndalen AM, Helland Å, Malinen E (2017)
Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib
Clin Transl Radiat Oncol, 4, 57-63
DOI 10.1016/j.ctro.2017.04.002, PubMed 29594209

Abravan A, Knudtsen IS, Eide HA, Løndalen AM, Helland Å, van Luijk P, Malinen E (2017)
A new method to assess pulmonary changes using 18F-fluoro-2-deoxyglucose positron emission tomography for lung cancer patients following radiotherapy
Acta Oncol, 56 (11), 1597-1603
DOI 10.1080/0284186X.2017.1349336, PubMed 28849707

Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
Oncotarget, 8 (34), 57121-57133
DOI 10.18632/oncotarget.19078, PubMed 28915659

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
Oncotarget, 8 (1), 1074-1082
DOI 10.18632/oncotarget.13718, PubMed 27911866

Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland Å (2017)
Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
Dis Markers, 2017, 3098542
DOI 10.1155/2017/3098542, PubMed 28293063

McGowan M, Kleinberg L, Halvorsen AR, Helland Å, Brustugun OT (2017)
NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
Genes Cancer, 8 (3-4), 497-504
DOI 10.18632/genesandcancer.136, PubMed 28680534

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM, Zhang P, Mookerjee B, Johnson BE (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
Lancet Oncol, 18 (10), 1307-1316
DOI 10.1016/S1470-2045(17)30679-4, PubMed 28919011

Publications 2016

Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J et al. (2016)
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
Nat Genet, 48 (4), 374-86
DOI 10.1038/ng.3521, PubMed 26928228

Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
BMC Cancer, 16, 71
DOI 10.1186/s12885-016-2104-9, PubMed 26858029

Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285

Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I (2016)
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
Oncoimmunology, 5 (12), e1248015
DOI 10.1080/2162402X.2016.1248015, PubMed 28123884

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
Oncotarget, 7 (24), 37250-37259
DOI 10.18632/oncotarget.9363, PubMed 27191990

Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD (2016)
Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
Mol Oncol, 11 (2), 220-234
DOI 10.1002/1878-0261.12025, PubMed 28145100

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894

Helland A (2016)
MicroRNA-profiles in lung adenocarcinomas
Expert Rev. Precis. Med. Drug Dev., 1 (5), 469-474
DOI 10.1080/23808993.2016.1240011

Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å (2016)
Subtype-specific micro-RNA expression signatures in breast cancer progression
Int J Cancer, 139 (5), 1117-28
DOI 10.1002/ijc.30142, PubMed 27082076

Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2016)
Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
F1000Res, 5, 38
DOI 10.12688/f1000research.7599.1, PubMed 27081474

McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT (2016)
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
Lung Cancer, 103, 52-57
DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696

Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
Diagn Pathol, 11 (1), 50
DOI 10.1186/s13000-016-0504-4, PubMed 27316334

Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R et al. (2016)
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
Nat Genet, 49 (1), 65-74
DOI 10.1038/ng.3722, PubMed 27869826

Publications 2015

Arnesen MR, Knudtsen IS, Rekstad BL, Eilertsen K, Dale E, Bruheim K, Helland Å, Løndalen AM, Hellebust TP, Malinen E (2015)
Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps
Acta Oncol, 54 (9), 1607-13
DOI 10.3109/0284186X.2015.1061690, PubMed 26213311

Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland Å (2015)
EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
Acta Oncol, 55 (2), 149-55
DOI 10.3109/0284186X.2015.1062537, PubMed 26313507

Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720

Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Am J Hum Genet, 97 (1), 22-34
DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781

Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT (2015)
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
Clin Cancer Res, 21 (11), 2635-43
DOI 10.1158/1078-0432.CCR-14-1905, PubMed 25680376

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
Genome Biol, 16 (1), 7
DOI 10.1186/s13059-014-0558-0, PubMed 25650807

Helland A (2015)
Gene jockeys Life science and the rise of biotech enterprise.
Tidsskr. Nor. Laegeforen., 135 (4), 356
DOI 10.4045/tidsskr.14.1367

Helland A (2015)
Cancer stem cells
Tidsskr. Nor. Laegeforen., 135 (8), 783
DOI 10.4045/tidsskr.15.0031

Helland A (2015)
Viruses and human cancer
Tidsskr. Nor. Laegeforen., 135 (9), 874
DOI 10.4045/tidsskr.15.0167

Lund-Iversen M, Grøholt KK, Helland Å, Borgen E, Brustugun OT (2015)
NUT expression in primary lung tumours
Diagn Pathol, 10, 156
DOI 10.1186/s13000-015-0395-9, PubMed 26341600

Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580

Syljuåsen RG, Hasvold G, Hauge S, Helland Å (2015)
Targeting lung cancer through inhibition of checkpoint kinases
Front Genet, 6, 70
DOI 10.3389/fgene.2015.00070, PubMed 25774168

Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland Å, Alexeyev OA, Hallberg B, Palmer RH (2015)
Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
PLoS One, 10 (5), e0123542
DOI 10.1371/journal.pone.0123542, PubMed 25955180

Publications 2014

Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K (2014)
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
Cell Rep, 6 (3), 514-27
DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
Int J Cancer, 135 (8), 1812-21
DOI 10.1002/ijc.28828, PubMed 24599520

Brustugun OT, Helland Å, Julsrud L (2014)
[Time counts!]
Tidsskr Nor Laegeforen, 134 (9), 915
DOI 10.4045/tidsskr.14.0057, PubMed 24828708

Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å (2014)
BRAF-mutations in non-small cell lung cancer
Lung Cancer, 84 (1), 36-8
DOI 10.1016/j.lungcan.2014.01.023, PubMed 24552757

Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M et al. (2014)
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Nat Commun, 5, 3518
DOI 10.1038/ncomms4518, PubMed 24670920

Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
Genome Biol, 15 (8), 435
DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004

Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuåsen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Børresen-Dale AL, Kristensen V, Edvardsen H (2014)
Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
Int J Cancer, 135 (9), 2085-95
DOI 10.1002/ijc.28862, PubMed 24658971

Sagerup CM, Nymoen DA, Halvorsen AR, Lund-Iversen M, Helland A, Brustugun OT (2014)
Human papilloma virus detection and typing in 334 lung cancer patients
Acta Oncol, 53 (7), 952-7
DOI 10.3109/0284186X.2013.879608, PubMed 24446743

Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM (2014)
Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
J Proteome Res, 13 (5), 2314-27
DOI 10.1021/pr401092y, PubMed 24669823

Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F (2014)
GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
Genome Biol, 15 (8), 442
DOI 10.1186/s13059-014-0442-y, PubMed 25168174

Publications 2013

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714

Brustugun OT, Helland Å (2013)
Rapid reduction in the incidence of cancer of unknown primary. A population-based study
Acta Oncol, 53 (1), 134-7
DOI 10.3109/0284186X.2013.783230, PubMed 23550957

Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland Å (2013)
Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
PLoS One, 8 (5), e62153
DOI 10.1371/journal.pone.0062153, PubMed 23671585

Rajaram M, Zhang J, Wang T, Li J, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, Myeroff L, Markowitz SD, Lowe SW, Zhang M, Krasnitz A, Lucito R, Mu D, Powers RS (2013)
Two Distinct Categories of Focal Deletions in Cancer Genomes
PLoS One, 8 (6), e66264
DOI 10.1371/journal.pone.0066264, PubMed 23805207

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
Osteopontin is a prognostic biomarker in non-small cell lung cancer
BMC Cancer, 13, 540
DOI 10.1186/1471-2407-13-540, PubMed 24215488

Publications 2012

Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L (2012)
[Mutation testing for non-small-cell lung cancer]
Tidsskr Nor Laegeforen, 132 (8), 952-5
DOI 10.4045/tidsskr.11.1017, PubMed 22562326

Helland Å, Solberg S, Brustugun OT (2012)
Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases
J Thorac Oncol, 7 (12), 1858-1861
DOI 10.1097/JTO.0b013e318275b346, PubMed 23154557

Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland Å, Brustugun OT (2012)
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations
J Thorac Oncol, 7 (9), 1471-3
DOI 10.1097/JTO.0b013e3182614a9d, PubMed 22895145

Sagerup CM, Småstuen M, Johannesen TB, Helland A, Brustugun OT (2012)
Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients
J Thorac Oncol, 7 (1), 57-63
DOI 10.1097/JTO.0b013e3182307f7e, PubMed 21900838

Waldeland E, Brustugun OT, Ramberg C, Helland Å (2012)
[Stereotactic irradiation in spinal metastases]
Tidsskr Nor Laegeforen, 132 (22), 2478-9
DOI 10.4045/tidsskr.12.1108, PubMed 23338027

Waldeland E, Ramberg C, Arnesen MR, Helland A, Brustugun OT, Malinen E (2012)
Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors
Acta Oncol, 51 (5), 603-9
DOI 10.3109/0284186X.2012.658115, PubMed 22304490

Publications 2011

Berg A, Brustugun OT, Lund-Iversen M, Helland Å (2011)
Palmar bullous blistering induced by erlotinib
J Thorac Oncol, 6 (5), 954
DOI 10.1097/JTO.0b013e318211136b, PubMed 21623268

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F et al. (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
Cancer Discov, 1 (1), 78-89
DOI 10.1158/2159-8274.CD-11-0005, PubMed 22328973

Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD (2011)
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
PLoS One, 6 (4), e18064
DOI 10.1371/journal.pone.0018064, PubMed 21533284

Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT (2011)
EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
J Thorac Oncol, 6 (5), 947-50
DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266

Haakensen VD, Bjøro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å (2011)
Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
BMC Cancer, 11, 332
DOI 10.1186/1471-2407-11-332, PubMed 21812955

Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011)
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
BMC Med Genomics, 4, 77
DOI 10.1186/1755-8794-4-77, PubMed 22044755

Knudtsen IS, Rødal J, Brustugun OT, Helland Å, Skretting A, Malinen E (2011)
Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study
Acta Oncol, 50 (6), 889-96
DOI 10.3109/0284186X.2011.583266, PubMed 21767189

Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
Proc Natl Acad Sci U S A, 109 (8), 2802-7
DOI 10.1073/pnas.1108781108, PubMed 21908711

Sagerup CM, Småstuen M, Johannesen TB, Helland Å, Brustugun OT (2011)
Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases
Thorax, 66 (4), 301-7
DOI 10.1136/thx.2010.151621, PubMed 21199818

Turzer M, Brustugun OT, Waldeland E, Helland A (2011)
Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
Case Rep Oncol, 4 (1), 25-34
DOI 10.1159/000324113, PubMed 21526003

Publications 2010

Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Børresen-Dale AL, Helland A (2010)
Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
Breast Cancer Res, 12 (4), R65
DOI 10.1186/bcr2632, PubMed 20799965

Marienhagen K, Helland A, Nordberg T, Guren MG, Hofsli E (2010)
[How do Norwegian oncologists perceive their working conditions?]
Tidsskr Nor Laegeforen, 130 (5), 487-9
DOI 10.4045/tidsskr.08.0305, PubMed 20224615

Turzer M, Brustugun OT, Helland A (2010)
Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
Case Rep Oncol, 3 (2), 195-201
DOI 10.1159/000317104, PubMed 20740196

Publications 2009

Helland A, Brustugun OT (2009)
[Lung cancer in smokers and never-smokers]
Tidsskr Nor Laegeforen, 129 (18), 1859-62
DOI 10.4045/tidsskr.08.0652, PubMed 19844277

Kamalakaran S, Kendall J, Zhao X, Tang C, Khan S, Ravi K, Auletta T, Riggs M, Wang Y, Helland A, Naume B, Dimitrova N, Børresen-Dale AL, Hicks J, Lucito R (2009)
Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
Nucleic Acids Res, 37 (12), e89
DOI 10.1093/nar/gkp413, PubMed 19474344

Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws AL, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HY, Nishikawa A, Niwa Y et al. (2009)
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies
Lancet Oncol, 10 (8), 772-84
DOI 10.1016/S1470-2045(09)70187-1, PubMed 19625214

Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB (2009)
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
PLoS One, 4 (5), e5583
DOI 10.1371/journal.pone.0005583, PubMed 19440550

Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC, Børresen-Dale AL (2009)
Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
Mol Oncol, 4 (2), 98-118
DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370

Publications 2008

Aavitsland P, Helland A (2008)
[The selected contagions]
Tidsskr Nor Laegeforen, 128 (20), 2304
PubMed 19096483

Publications 2007

Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bøhn M, Erikstein B, Helland A, Børresen-Dale AL, Fosså SD (2007)
Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy
Int J Radiat Oncol Biol Phys, 67 (4), 1163-71
DOI 10.1016/j.ijrobp.2006.11.009, PubMed 17336217

Publications 2006

Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
PLoS Med, 3 (3), e47
DOI 10.1371/journal.pmed.0030047, PubMed 16417408

Helland A, Johnsen H, Frøyland C, Landmark HB, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, Ottestad LO, Rodningen OK, Sherlock G, Børresen-Dale AL (2006)
Radiation-induced effects on gene expression: an in vivo study on breast cancer
Radiother Oncol, 80 (2), 230-5
DOI 10.1016/j.radonc.2006.07.007, PubMed 16890317

Publications 2005

Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
DOI 10.1002/humu.9316, PubMed 15712344

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507

Publications 2004

Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786

Publications 2003

Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH (2003)
X chromosome inactivation in cervical cancer patients
Cancer Genet Cytogenet, 146 (1), 73-6
DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700

Publications 2001

Helland Å, Børresen-Dale AL (2001)
Livmorhalskreft og arvelighet med fokus på HLA-systemet
In Medicinsk årbog, Norli, Oslo, 2001, s. 121-128
BIBSYS 042195993

Publications 2000

Helland Å (2000)
Malignancy of the cervix uteri: genetic susceptibility and somatic DNA alterations in tumour in relation to prognosis
Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, [Oslo], 1 b. (flere pag.)
BIBSYS 001167235, ISBN 82-7633-146-7

Publications 1989

Helland Å, Kiserud CE (1989)
Voldtekt: en litteraturgjennomgang med hovedvekt på psykiske reaksjoner hos offeret og hvordan helsevesenet bør møte denne pasientgruppen
In Spesialoppgave, Universitetet i Oslo, Oslo, 79 s.
BIBSYS 900046767

Page visits: 438002